

**Phospho-CCND3(T283) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP3870a****Specification**

---

**Phospho-CCND3(T283) Blocking Peptide - Product Information**

Primary Accession [P30281](#)  
Other Accession [P48961](#), [P30282](#), [Q3MHH5](#), [NP\\_001129489.1](#)

**Phospho-CCND3(T283) Blocking Peptide - Additional Information**

**Gene ID** 896

**Other Names**

G1/S-specific cyclin-D3, CCND3

**Target/Specificity**

The synthetic peptide sequence is selected from aa 277-288 of HUMAN CCND3

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**Phospho-CCND3(T283) Blocking Peptide - Protein Information**

**Name** CCND3 {ECO:0000303|PubMed:1386336, ECO:0000312|HGNC:HGNC:1585}

**Function**

Regulatory component of the cyclin D3-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition (PubMed:<a href="http://www.uniprot.org/citations/8114739" target="\_blank">8114739</a>). Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase (PubMed:<a href="http://www.uniprot.org/citations/8114739" target="\_blank">8114739</a>). Hypophosphorylates RB1 in early G(1) phase (PubMed:<a href="http://www.uniprot.org/citations/8114739" target="\_blank">8114739</a>). Cyclin D- CDK4 complexes are major integrators of various mitogenic and antimitogenic signals (PubMed:<a href="http://www.uniprot.org/citations/8114739" target="\_blank">8114739</a>). Component of the ternary complex, cyclin D3/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex (PubMed:<a href="http://www.uniprot.org/citations/16782892" target="\_blank">16782892</a>). Shows transcriptional coactivator activity with ATF5

independently of CDK4 (PubMed:<a href="http://www.uniprot.org/citations/15358120" target="\_blank">15358120</a>).

#### **Cellular Location**

Nucleus. Cytoplasm

### **Phospho-CCND3(T283) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

### **Phospho-CCND3(T283) Blocking Peptide - Images**

### **Phospho-CCND3(T283) Blocking Peptide - Background**

The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. This protein has been shown to interact with and be involved in the phosphorylation of tumor suppressor protein Rb. The CDK4 activity associated with this cyclin was reported to be necessary for cell cycle progression through G2 phase into mitosis after UV radiation. Several transcript variants encoding different isoforms have been found for this gene.

### **Phospho-CCND3(T283) Blocking Peptide - References**

Liu, C.Y., et al. Carcinogenesis 31(7):1259-1263(2010)  
Kim, J., et al. Cytokine 50(1):42-49(2010)  
Kamatani, Y., et al. Nat. Genet. 42(3):210-215(2010)  
Gumina, M.R., et al. Cell Cycle 9(4):820-828(2010)  
Radulovich, N., et al. Mol. Cancer 9, 24 (2010) :